Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ongentys

Roche Basel Switzerland

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

First single-dose flu medication approved for post-exposure prophylaxis

Sanofi reception

Sanofi’s quadrivalent flu vaccine Supemtek scores EU approval

Company expects first EU launches in 2022/2023 flu season

Roche Basel Switzerland

Roche’s flu pill Xofluza moves closer towards EU approval

CHMP recommends drug for approval in the EU

- PMLiVE

EU secures 405 million doses of CureVac’s COVID-19 vaccine

CureVac revealed early stage data for its vaccine earlier this month

EU flag

EU agrees on supply deal for 200 million doses of Pfizer, BioNTech’s COVID-19 vaccine

European Commission will have an option to request another 100 million doses

- PMLiVE

Roche and Atea link up for oral COVID-19 drug; UK to test coronavirus vaccine T cell responses

New developments for COVID-19 treatments and vaccines

- PMLiVE

Roche and Prothena set to advance Parkinson’s disease candidate into phase 2b

Drug moves into late-stage testing despite failing to hit primary endpoint in previous trial

- PMLiVE

Roche to collaborate with Dyno on gene therapies for CNS/liver diseases

Dyno will use its CapsidMap platform to develop novel AAV vectors for improved gene therapies

- PMLiVE

EU announces agreement with Gilead for remdesivir supply

Drug was granted conditional marketing authorisation in the EU in July

- PMLiVE

J&J signs deal with EU for 200 million COVID-19 vaccine doses

EU member states will have an option to secure 200 million additional doses

- PMLiVE

Roche’s Ocrevus boasts positive long-term data in MS

After two years of treatment 75% of patients had no evidence of disease activity

Roche Basel Switzerland

Roche plans to launch rapid COVID-19 antigen test later this month

Swiss pharma also intends to file for emergency approval in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links